Table 1 Summary of clinical trials of oncolytic viral therapy for patients with glioblastoma
From: Emerging therapies for glioblastoma: current state and future directions
Treatment | Status | Enrolled Patients | Primary outcome measures | NCT number |
|---|---|---|---|---|
Genetically Engineered Adenovirus DNX-2440 | Recruiting phase I | 24 | Safety, OS, and ORR | NCT03714334 |
Combination of modified vaccinia virus TG6002 and 5-FC | unknown phase I/II | 78 | DLTs and tumor progression at 6 months | NCT03294486 |
Adenovirus DNX-2401 ± IFN-γ | Completed phase I | 37 | ORR by interval tumor size | NCT02197169 |
DNX2401 and TMZ | Completed phase I | 31 | Number of patients with AEs | NCT01956734 |
Genetically Engineered HSV-1 MVR-C5252 (C5252) | Not yet recruiting phase I | 51 | Safety and tolerability DLTs and MTD | NCT05095441 |
New Castle Disease Virus | Study withdrawn for unknown reasons phase I/II | 0 | PFS | NCT01174537 |
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO) administered by CED into tumor | Active, not recruiting phase I | 61 | MTD, DLTs and RP2D | NCT01491893 |
Adenovirus DNX-2401 and surgery | Recruiting phase I | 36 | MTD and Incidence of AEs | NCT03896568 |
Genetically Engineered HSV-1 G207 | Completed phase I/II | 65 | Not provided | NCT00028158 |
Replication-competent Adenovirus (Delta-24-RGD) administered by CED into tumor | Completed phase I/II | 20 | treatment related serious AEs | NCT01582516 |
Neural stem cells (NSCs) loaded with an oncolytic adenovirus | Active, not recruiting phase I | 13 | maximum number of NSCs loaded with oncolytic adenovirus | NCT03072134 |
H-1 Parvovirus (H-1PV) | Completed phase I/II | 18 | Safety and tolerability | NCT01301430 |
HSV-1 mutant HSV1716 | Study terminated for unknown reasons phase I | 2 | MTD | NCT02031965 |
Combination Adenovirus change NCT02798406 DNX2401 and pembrolizumab | Completed phase II | 49 | ORR by interval tumor size | |
AdV-tk (adenoviral vector expressing HSV-TK) plus valacyclovir (antiviral drug) and SOC | Completed phase II | 52 | Safety and OS | NCT00589875 |
Genetically Engineered HSV-1 C134 | Recruiting phase I | 24 | Safety and tolerability | NCT03657576 |
Oncolytic viral vector rQNestin34.5v.2 | Recruiting phase I | 56 | MTD | NCT03152318 |
PVSRIPO | Active, not recruiting phase I | 12 | Toxicity within 14 days after PVSRIPO treatment | NCT03043391 |
Genetically Engineered HSV-1 M032 | Recruiting phase I | 36 | MTD | NCT02062827 |
Single dose of G207 infused through catheters into tumors | Not yet recruiting phase II | 30 | OS | NCT04482933 |
PVSRIPO administered by CED into tumor | Active, not recruiting phase II | 122 | ORR rate and DORR at 24 and 36 months | NCT02986178 |
Single dose of G207 infused through catheters into tumors | Recruiting phase I | 15 | Safety and tolerability | NCT03911388 |
Single dose of G207 infusedthrough catheters into tumors | Active, not recruiting phase I | 12 | Safety and tolerability | NCT02457845 |
Live, replication-competent wild-type reovirus REOLYSIN® | Completed phase I | 18 | MTD, DLTs and 6- month response rate | NCT00528684 |
Combination of PVSRIPO and atezolizumab | withdrawn Re-submission Planned phase I/II | 0 | AEs within 14 days after atezolizumab treatment, proportion patients alive at 24 months after PVSRIPO infusion | NCT03973879 |
Toca511 & Toca FC versus SOC | Study terminated for unknown reasons phase II/III | 403 | OS | NCT02414165 |